Kanna Mesembryanthemum tortuosum L.
Also called: Sceletium tortuosum (synonym), sceletium
Kanna is a succulent plant endemic to South Africa, traditionally chewed or smoked by San and Khoikhoi people. Human trials to date have mostly used a standardized extract.
- Category
- Botanical
- Part used
- Whole plant material; trials used a standardized 2:1 dry extract
- Strongest evidence
- C Limited
- Native range
- Native to the Cape Provinces of South Africa (POWO: "Cape Prov.")
- Reviewed
- 2026-10-28
Class 2 Moderately studied in people. A 2023 meta-analysis (Brain Disorders) pooled 4 randomized trials (117 participants; 1 RCT and 3 randomized crossover trials) of Sceletium tortuosum 25 mg versus placebo; the trials this entry cites used the extract Zembrin. [5]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Anxiety in adults (pooled trials) | C | A meta-analysis of four small randomized trials (117 participants) found no difference in anxiety between kanna and control (RR 1.01, 95% CI 0.56–1.83); the authors could not confirm an effect. [5] |
| Laboratory-induced stress in healthy young adults | C | Two placebo-controlled experiments (single 25 mg dose, 20 volunteers): no effect in the first; in the second, lower anticipatory anxiety and an altered heart-rate response. Authors called this first tentative evidence. [1] |
| Brain threat response in healthy adults | C | In a crossover imaging study of 16 healthy adults, a single 25 mg dose reduced amygdala reactivity to fearful faces; this is a brain-imaging measure, not a clinical outcome. [4] |
| Cognitive function in healthy adults | C | A 3-week crossover trial in 21 healthy adults (mean age 54.6, 25 mg daily) reported better cognitive set flexibility and executive function than placebo. [6] |
Main constituents: Mesembrine-type alkaloids: 25 alkaloids in four structural classes identified, the mesembrine class predominant [2]; The standardized extract studied is reported to act as a dual serotonin (5-HT) reuptake and PDE4 inhibitor [4]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 8 mg or 25 mg of a standardized extract once daily for 3 months (safety trial). [3]
- Single 25 mg doses in acute laboratory studies. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsSee details
FDA does not approve dietary supplements.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [8]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Mesembrine-type alkaloids: 25 alkaloids in four structural classes (mesembrine, Sceletium A4, joubertiamine, tortuosamine), the mesembrine class predominant Alkaloids [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list (dated July 9, 2026; checked 2026-10-29) does not name kanna, Sceletium tortuosum or Mesembryanthemum tortuosum, but has 1 entry for the trade-named ingredient Zembrin® (NDI 705 submitted 2011-04-20). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
- Zembrin® is described in a published clinical trial as a trademarked 2:1 standardized extract of Sceletium tortuosum (L.) N.E. Br. (Nell et al., 2013). [P6]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P5]
Supply and conservation
- Sceletium tortuosum is a succulent forb endemic to South Africa (Olatunji et al., 2022). [P1]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Olatunji TL, et al. Sceletium tortuosum: a review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities. J Ethnopharmacol 2022;287:114711 (PMID 34758918), 2022-04-06. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1-142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- Nell H, et al. A randomized, double-blind, parallel-group, placebo-controlled trial of extract Sceletium tortuosum (Zembrin) in healthy adults. J Altern Complement Med 2013;19(11):898-904 (PMID 23441963), 2013-11. pubmed.ncbi.nlm.nih.gov
Sources
- Reay J, et al. Sceletium tortuosum (Zembrin) ameliorates experimentally induced anxiety in healthy volunteers. Hum Psychopharmacol 2020;35(6):1-7 (PMID 32761980), 2020-11. pubmed.ncbi.nlm.nih.gov
- Olatunji TL, et al. Sceletium tortuosum: a review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities. J Ethnopharmacol 2022;287:114711 (PMID 34758918), 2022-04-06. pubmed.ncbi.nlm.nih.gov
- Nell H, et al. A randomized, double-blind, parallel-group, placebo-controlled trial of extract Sceletium tortuosum (Zembrin) in healthy adults. J Altern Complement Med 2013;19(11):898-904 (PMID 23441963), 2013-11. pubmed.ncbi.nlm.nih.gov
- Terburg D, et al. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala. Neuropsychopharmacology 2013 (PMID 23903032), 2013-12. pubmed.ncbi.nlm.nih.gov
- Gouhie FA, et al. Sceletium tortuosum effects on anxiety: a systematic review and meta-analysis. Brain Disorders 2023;11:100092, 2023-09. sciencedirect.com
- Chiu S, et al. Proof-of-concept randomized controlled study of cognition effects of the proprietary extract Sceletium tortuosum (Zembrin). Evid Based Complement Alternat Med 2014:682014 (PMID 25389443), 2014-10-19. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Mesembryanthemum tortuosum L. (accessed 2026-10-28; Kew cannot warrant the accuracy of the data). powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.